The much anticipated SIRFLOX study has failed to demonstrate a statistically significant increase in progression free survival (PFS; measures the time interval...

The much anticipated SIRFLOX study has failed to demonstrate a statistically significant increase in progression free survival (PFS; measures the time interval from trail start to the time when the cancer starts to regrow) for main product SIR-Spheres microspheres combined with chemotherapy compared to chemotherapy alone in secondary liver cancer patients. While the trial did show the product increased PFS in the liver in a statistically significant manner, this is a secondary endpoint of the study which did not translate into any patient benefit. The full trial details to be presented at the American Society of Clinical Oncology (ASCO) meeting held 29 May- 2 June 2015. While we do not expect unfavourable results to negatively impact uptake of the device in its current 'salvage setting', trading levels have optimistically baked-in favourable trial results, with downside of 48-62% as we view fair value in the $15-20 range. Sirtex (SRX, Reduce, Price Target A$15.63) (Source:Derek jellinek) @morgans


MORE ON



2 topics

Senior Analyst
Morgans

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.